Home › Trials › NCT03862677
Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Identifying immune markers in ovarian cancer patients

Official title: Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Run by Leiden University Medical Center · NCT03862677 · Data updated 2026-11-12

This study is trying to find immune markers in women with ovarian cancer to see how they relate to treatment outcomes.

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment300 (estimated)
SponsorLeiden University Medical Center
Academic / other
Drugs / interventionschemotherapy, immunotherapy
Locations1 site (Leiden)
StatusRecruiting
StartedAugust 15, 2020
Main results expectedJanuary 31, 2027
Study endsJanuary 31, 2027
Registry record updatedFebruary 13, 2026
Trial IDNCT03862677 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with primary or recurrent epithelial ovarian cancer who are scheduled for surgery, chemotherapy, or immunotherapy.

Probably not a fit

Patients with other active malignancies, severe infections, or those receiving immune suppressive treatments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The IMPRoVE study is a prospective, non-interventional cohort study aimed at identifying prognostic immune markers in patients diagnosed with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It involves the collection of tumor material, ascites, and blood samples from patients undergoing surgery, chemotherapy, and/or immunotherapy. This observational approach allows researchers to monitor immune responses and their correlation with patient outcomes without administering any treatment.

Why it matters

Potential benefit: If successful, this study could lead to improved prognostic tools for better treatment decisions in ovarian cancer patients.

How similar studies have gone: Similar studies have shown promise in identifying immune markers in various cancers, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
* Age ≥18 years.
* WHO performance status 0-2.
* Accessible for treatment and follow-up.
* Written informed consent.

Exclusion Criteria:

* Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
* Any known severe infection like HIV, hepatitis A, B and C.
* Receiving immune suppressive treatment.
* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

Where it's running

  • Leiden University Medical Center
    Leiden, Netherlands     Recruiting

Study contacts

  • Principal investigator: Judith R Kroep, MD PhD — Leiden University Medical Center
  • Study coordinator: Judith R Kroep, MD PhD
  • Email: j.r.kroep@lumc.nl
  • Phone: +31715263464

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Epithelial Ovarian Cancer 54Leiden University Medical Center 65
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.